Design Therapeutics Inc
NASDAQ:DSGN
Design Therapeutics Inc
NASDAQ:DSGN
Price:
4.69 USD
Market Closed
Updated:
May 9, 2024
Design Therapeutics Inc
Research & Development
|
Design Therapeutics Inc
Research & Development Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Design Therapeutics Inc
NASDAQ:DSGN
|
Research & Development
-$57.1m
|
CAGR 3-Years
-111%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$6.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$4.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-17%
|
See Also
What is Design Therapeutics Inc's Research & Development?
Research & Development
-57.1m
USD
-57.1m
USD
Based on the financial report for Dec 31, 2023, Design Therapeutics Inc's Research & Development amounts to -57.1m USD.
What is Design Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-111%
-111%
Over the last year, the Research & Development growth was -17%. The average annual Research & Development growth rates for Design Therapeutics Inc have been -111% over the past three years .
You don't have any saved screeners yet
